FDA approves Orgovyx, the first oral hormone therapy of its type for treating advanced prostate cancer
https://www.facingourrisk.org/XRAY/hormone-therapy-for-advanced-prostate-cancer
Full article: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-hormone-therapy-treating-advanced-prostate-cancer
In December 2020, the FDA approved Orgovyx to treat advanced prostate cancer. The findings were based on the HERO clinical trial of more than 900 men. Data from this trial showed the new therapy was safer than standard androgen deprivation treatment for men with advanced prostate cancer and risk of cardiovascular disease. (2/18/21)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- What are my options for treating prostate cancer?
- Is treatment with Orgovyx an option for me?
- How long will I have to take Orgovyx?
- What are the side effects of taking Orgovyx?
- What are the risks and benefits of standard ADT treatment compared to Orgovyx treatment?
Open Clinical Trials
The following studies look at androgen deprivation therapy in people with prostate cancer.
- NCT04666129: Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer. This study tests the safety and tolerability of the drug relugolix when it is used with other drugs that are approved for androgen deprivation therapy (ADT).
- NCT05100472: A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer. This study focuses on finding out whether combining shorter-than-standard course of hormone therapy with standard prostate radiation therapy is a safe and effective way to prevent high-risk prostate cancer from coming back and/or spreading.
- NCT02949284: Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery This assess the effectiveness of hormonal therapy ARN-509 with or without abiraterone and prednisone when treating high-risk prostate cancer patients who are undergoing surgery.
- NCT03860987: Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer. The goal of this study is to develop improved techniques that localize and detect prostate cancer; and to develop new ways to treat prostate cancer.
Several other clinical trials for patients with prostate cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.